Andrew Witty - GlaxoSmithKline PLC CEO, Executive Director

GSK -  USA Stock  

USD 39.84  0.73  1.80%

  CEO
Sir Andrew Philip Witty is no longer as Chief Executive Officer, Executive Director of GlaxoSmithKline PLC, effective 31st March 2017. He joined GSK in 1985. He joined GSK in 1985. He has worked in the UK, South Africa, the USA and Singapore in various senior roles. In 2003, he was appointed President of GSK Europe and joined GSKs Corporationrationrate Executive Team. In 2003 he was awarded the Public Service Medal by the Government of Singapore and in August 2012 was also awarded the Public Service Star. In the 2012 New Year Honours list, he was awarded a Knighthood for services to the economy and to the UK pharmaceutical industry. He served as the Lead NonExecutive Board member for the Department of Business, Innovation and Skills to December 2013. He was also President of the European Federation of Pharmaceutical Industries and Associations until July 2013. Sir Andrew is a member of the UK Prime Ministers Business Advisory Group and was appointed to the UK Business Ambassador Group in January 2014.
Age: 50  CEO Since 2008  MBA    
44 20 8047 5000  http://www.gsk.com

Andrew Witty Latest Insider Activity

Tracking and analyzing the buying and selling activities of Andrew Witty against GlaxoSmithKline PLC stock is an integral part of due diligence when investing in GlaxoSmithKline PLC. Andrew Witty insider activity provides valuable insight into whether GlaxoSmithKline PLC is net buyers or sellers over its current business cycle. Note, GlaxoSmithKline PLC insiders must abide by specific rules, including filing SEC forms every time they buy or sell GlaxoSmithKline PLC'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

GlaxoSmithKline PLC Management Efficiency

GlaxoSmithKline PLC has Return on Asset of 5.9 % which means that on every $100 spent on asset, it made $5.9 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 29.04 %, implying that it generated $29.04 on every 100 dollars invested. GlaxoSmithKline PLC management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. GlaxoSmithKline PLC Return on Investment is decreasing as compared to previous years. The last year's value of Return on Investment was reported at 11.53. The current Return on Average Equity is estimated to increase to 0.42, while Return on Average Assets are projected to decrease to 0.07. The current Total Liabilities is estimated to decrease to about 57.5 B. The current Current Liabilities is estimated to decrease to about 22 B
The company has 26.22 B in debt with debt to equity (D/E) ratio of 1.25, which is OK given its current industry classification. GlaxoSmithKline PLC has a current ratio of 0.89, suggesting that it has not enough short term capital to pay financial commitments when the payables are due.
The market value of GlaxoSmithKline PLC is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine GlaxoSmithKline PLC value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Similar Executives

Found 4 records

CEO Since

Pascal SoriotAstrazeneca PLC
2012
Javier RibesGrifols SA
2015
Victor DeuGrifols SA
2017
Albert RouraGrifols SA
2014
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GlaxoSmithKline PLC operates under Drug Manufacturers - General classification in the United States and is traded on New York Stock Exchange. It employs 94066 people. GlaxoSmithKline PLC (GSK) is traded on New York Stock Exchange in USA. It is located in 980 Great West Road and employs 94,066 people. GlaxoSmithKline PLC is listed under Pharmaceutical Products category by Fama And French industry classification.

GlaxoSmithKline PLC Leadership Team

Elected by the shareholders, the GlaxoSmithKline PLC's board of directors comprises two types of representatives: GlaxoSmithKline PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GlaxoSmithKline. The board's role is to monitor GlaxoSmithKline PLC's management team and ensure that shareholders' interests are well served. GlaxoSmithKline PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GlaxoSmithKline PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
Vindi Banga, Senior Independent Non-Executive Director
Lynn Elsenhans, Independent Non-Executive Director
Luke Miels, President - Global Pharmaceuticals
Hal Barron, Chief Scientific Officer, President - Research & Development, Executive Director
Daniel Podolsky, Non-Executive Independent Director
Emma Walmsley, Chief Executive Officer, Executive Director
Luc Debruyne, President - Global Vaccines
Andrew Witty, CEO, Executive Director
Brian McNamara, Chief Executive Officer - GSK Consumer Healthcare
Charles Bancroft, Non-Executive Independent Director
Roy Anderson, Non-Executive Independent Director
Philip Hampton, Independent Non-Executive Director
Simon Dingemans, CFO, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee
Vivienne Cox, Independent Non-Executive Director and Workforce Engagement Director
Bill Louv, Senior Vice President - Core Business Services
Diana Conrad, Senior Vice President - Human Resources
Roger Connor, President - Global Manufacturing & Supply
Abbas Hussain, President Global Pharmaceuticals
Phil Thomson, Senior Vice President - Global Communications
Judy Lewent, Non-Executive Independent Director
Hans Wijers, Independent Non-Executive Director
Stephanie Burns, Non-Executive Independent Director
Moncef Slaoui, Chairman of Global Vaccines, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee
Urs Rohner, Non-Executive Independent Director
Marvinder Banga, Senior Non-Executive Independent Director
Anne Beal, Non-Executive Independent Director
Deryck Maughan, Senior Independent Non-Executive Director
Jesse Goodman, Non-Executive Independent Director and Scientific and Medical Expert
Laurie Glimcher, Non-Executive Independent Director and Scientific & Medical Expert
Nick Hirons, Senior Vice President - Global Ethics and Compliance
Sally Jackson, Senior Vice President - Global Communications and CEO Office
James Ford, Senior Vice President General Counsel
Victoria Whyte, Company Secretary
Daniel Troy, Sr. VP and General Counsel
Shah Hussain, President - Europe, Japan & EMAP
Manvinder Banga, Non-Executive Director
David Redfern, Chief Strategy Officer
Patrick Vallance, President - Pharmaceuticals R&D
Stacey Cartwright, Non-Executive Independent Director
Regis Simard, President - Pharmaceutical Supply Chain
Jonathan Symonds, Independent Non-Executive Chairman of the Board
Iain Mackay, Chief Financial Officer, Executive Director
Karenann Terrell, Chief Digital and Technology Officer
Deborah Waterhouse, Chief Executive Officer - ViiV Healthcare
Claire Thomas, Senior Vice President - Human Resources

GlaxoSmithKline Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GlaxoSmithKline PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

GlaxoSmithKline PLC Investors Sentiment

The influence of GlaxoSmithKline PLC's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in GlaxoSmithKline. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - GSK

GlaxoSmithKline PLC Investor Sentiment

Predominant part of Macroaxis users are currently bullish on GlaxoSmithKline PLC. What is your judgment towards investing in GlaxoSmithKline PLC? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as GlaxoSmithKline PLC using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Note that the GlaxoSmithKline PLC information on this page should be used as a complementary analysis to other GlaxoSmithKline PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for GlaxoSmithKline PLC Stock analysis

When running GlaxoSmithKline PLC price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
The market value of GlaxoSmithKline PLC is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine GlaxoSmithKline PLC value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.